OTCMarketsExpert

OTCMarketsExpert

Technically the chart of OTC:QMED is starting to look more bullish since the start of July, possibly a base is formed and a bottoming complete. Significant resistance will hamper the recovery, but if considering a long maybe a break of the downtrend in price and RSI would be a buy signal. AVERAGE ANALYSTS PRICE TARGET $2 AVERAGE ANALYSTS RECOMMENDATION ...

OTCMarketsExpert

Hotstock expect more upside after securing $600 million equity investment proposal. Very likely that analyst upgrades will follow and entice new money into the stock with the promise of growth and expansion. “I am very proud today to share with all Nemaska Lithium stakeholders, the positive outcome of months of thorough review of alternatives and of discussions...

OTCMarketsExpert

Bristol-Myers Squibb ( BMY ), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients with micro-satellite stable metastatic colorectal cancer, the most common form of mCRC....

OTCMarketsExpert

Google has been on a tear from the Dec lows, it has now hit the 786 retrace and has sold of quite quickly as a result. It had a initial inverse H@S on the macd and then on price action which provided a lovely opportunity to go long. Due to the increased fear of regulation on Big Tech and social media's role in the New Zealand massacre, sentiment has changed...